© WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editorial Board Chairs: Antonello Mai, Rainer Metternich. Assoc. Editors: David Peralta, Scott Williams (Sr)
Impact Factor: 2.98
ISI Journal Citation Reports © Ranking: 2015: 18/59 (Chemistry Medicinal); 77/255 (Pharmacology & Pharmacy)
Online ISSN: 1860-7187
June 17, 2010
VIP: Proteins as Possible Targets for Cytotoxic trans-Platinum(II) Complexes with Aliphatic Amine Ligands: Further Exceptions to the DNA Paradigm
Leticia Cubo, Michael Groessl, Paul J. Dyson, Adoración G. Quiroga,* Carmen Navarro-Ranninger, and Angela Casini*
Efforts to improve the activity of platinum-based anticancer drugs have long been focused on cis geometric compounds; trans-configured species are thus considered "rule-breakers", and have thus been widely left alone. In their Full Paper, Quiroga, Casini, and colleagues show that certain trans-PtII species warrant attention, particularly for cases in which preferential drug binding to peptide targets over oligonucleotides is desired.
Received March 12, 2010; published online June 16, 2010, DOI: 10.1002/cmdc.201000104.